Literature DB >> 35778377

Diffuse spinal cord metastasis after resection of SMARCB1 sinonasal carcinoma manifesting with a right foot drop-a case report.

Matheus Alves da Silva1, Rafael Gemaque Lima Bentes2, Hennan Salzedas Teixeira2, Barbara Maini Carvalho2, André Luiz Guimarães Queiroz2, Marcelo Freitas Schmid2, Karlla Danielle Ferreira Lima2, William Souza Martins Ferreira2, Christiane Monteiro de Siqueira Campos3, Mateus Reghin Neto4, Alex Machado Baeta2.   

Abstract

INTRODUCTION: The sinonasal carcinoma are rare tumors of the head and neck. The undifferentiated sinonasal carcinoma subtypes are constantly being explored and new mutations, with different prognosis markers and biological behaviors are being described. The SMARCB1 negative sinonasal carcinoma subtypes have been recently described with few reports of leptomeningeal and spinal cord invasion. CASE
PRESENTATION: This study presents the case of a 59-year-old woman, with no previous disease, presenting initially with epistaxis that evolved to cranial nerve deficits and a left eye complete oftalmoplegia. After diagnostic investigation, she had a diagnosis of a left ethmoid sinus sinonasal carcinoma. Following resection of the tumor, she evolved with a right foot drop that eventually has been linked to diffuse spinal cord impairment. The histopathological diagnosis confirmed a SMARCB1 negative sinonasal carcinoma. Due to the diffuse metastasis, she underwent palliative care and died eight months after the surgery. DISCUSSION: Spinal cord metastasis may manifest with different clinical signs. Our case shows a rare manifestation of SMARCB1-deficient sinonasal carcinoma, a new subtype of sinonasal carcinoma, summarizing the importance of a high grade of suspicion of spinal cord invasion on these patients. SMARCB1 sinonasal carcinomas are rare new tumors of the head and neck, whose biological behaviors are yet to be explored. To the best of our knowledge, this is one of the few case reports describing simultaneous spread of this tumor to the central nervous system and spinal cord.
© 2022. The Author(s), under exclusive licence to International Spinal Cord Society.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35778377      PMCID: PMC9249738          DOI: 10.1038/s41394-022-00532-8

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  5 in total

1.  SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.

Authors:  Abbas Agaimy; Arndt Hartmann; Cristina R Antonescu; Simion I Chiosea; Samir K El-Mofty; Helene Geddert; Heinrich Iro; James S Lewis; Bruno Märkl; Stacey E Mills; Marc-Oliver Riener; Thomas Robertson; Ann Sandison; Sabine Semrau; Roderick H W Simpson; Edward Stelow; William H Westra; Justin A Bishop
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

2.  SMARCB1 (INI1)-deficient sinonasal carcinoma: a series of 13 cases with assessment of histologic patterns.

Authors:  Aanchal Kakkar; Vijay Mariadas Antony; Raja Pramanik; Pirabu Sakthivel; Chirom Amit Singh; Deepali Jain
Journal:  Hum Pathol       Date:  2018-08-16       Impact factor: 3.466

Review 3.  Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances.

Authors:  José Luis Llorente; Fernando López; Carlos Suárez; Mario A Hermsen
Journal:  Nat Rev Clin Oncol       Date:  2014-06-17       Impact factor: 66.675

4.  SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms.

Authors:  Abbas Agaimy; Michael Koch; Michael Lell; Sabine Semrau; Wojciech Dudek; David L Wachter; Antje Knöll; Heinrich Iro; Florian Haller; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

5.  SMARC-B1 deficient sinonasal carcinoma metastasis to the brain with next generation sequencing data: a case report of perineural invasion progressing to leptomeningeal invasion.

Authors:  Horacio Gomez-Acevedo; John D Patterson; Sehrish Sardar; Murat Gokden; Bhaskar C Das; David W Ussery; Analiz Rodriguez
Journal:  BMC Cancer       Date:  2019-08-22       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.